際際滷

際際滷Share a Scribd company logo
Mithramycin (MTM) is an anticancer agent, produced by
bacteria of the genus Streptomyces. MTM was popular in the
1960s to aid in the treatment of testicular carcinoma, chronic and
acute myeloid leukemias, and hyperkalemia. MTMs anti-cancer
potency lies in the ability to shut down the transcription of the
proto-oncogenes through cross-linking GC-rich DNA.
Unfortunately the large number of side effects caused the use of
MTM to be discontinued. In recent years, MTM has been revisited
as a potential anticancer agent because of the potential for semi-
synthetic manipulation and development of biosynthetic
analogues. One example of such work is demonstrated by
inactivating the mtmW gene. This gene encodes for the enzyme
responsible for the final step in the MTM biosynthetic pathway,
but once deactivated, 3 new analogues are formed: MTM SA,
MTM SK, and MTM SDK. MTM SK and MTM SDK improved the
anti-cancer ability of the drug but, due in part to its negative
charge at physiological pH, MTM SA shows reduced anticancer
capabilities.
Current research has shown that new derivatives of the
MTM SA analogue produced by manipulating the side chain
ending in the carboxylic acid have resulted in molecules with
greater anti-cancer abilities than those of even MTM SK and MTM
SDK. Further work was focused on optimizing the production
and isolation of MTM-SA followed by further work to rationally
design new drug molecules through modification of the terminal
carboxylic acid side chain of MTM SA. Once developed the
toxicity of the new compounds are investigated using the Jurkat
human leukemia cell line.
Improved Isolation, Derivatization, and Characterization of New
Mithramycin Analogues
Allison Foster, Sterling Brooks, Daniel Scott
Department of Chemistry and Biochemistry, DePauw University, Greencastle, IN 46135, USA
Summer 2014
Introduction
Acknowledgments
Mithramycin Analogue Biosynthesis
Bacteria Growth and Drug Production
Conclusions and Future Work
 Column 52666, a strong anion exchange column with a
quaternary amine, successfully isolated SA
 SA isolation final protocol: equilibrate 5 times with pH7
potassium phosphate monobasic, load drug, wash 5 times
with 90% 1mM NaCl/10% ACN, elute 3 times with 75% PBS
pH 2/25% ACN
 An amino side chain is attached through a reaction
composed of DCM, PyBOP, DIPEA, and a desired side chain
 Synthesized possible SA derivatives from phenylalanine with
a successful reaction
 Will continue testing different side chains on the SA analogs
 Will complete cytotoxicity assays on Jurkat leukemia cell
line, followed by a lung cancer cell line using isolated SK as
a control for each
The MTM analogues SA, SK, and SDK are are produced by the inactivation of the mtmW
gene responsible for the last enzyme in the biosynthetic pathway of MTM.
Isolation of SA
The SA analogue has a caroboxylic acid that that allows for a negative
charge at physiological pH. An anion exchange column was used to
take advantage of the negative charge and separate this analogue from
MTM SK and MTM SDK. The quaternary amine was the strongest and
most effective anion exchange column
S. Argillaceus is grown on R5A solid media for 5 days. A portion is cut
out and transferred to liquid TSB media for two days of further
promoted growth. A sample of this is transferred to R5A liquid media
for 5 or more days in order to promote drug production.
 
R5A Solid Media TSB Liquid Media R5A Liquid Media
 Jeff Hansen
 Wendy Tomamichel
 Dave Roberts
 DePauw University
 Science Research Fellows (SRF)
Column characteristics for isolation of SA. Column 52667, a strong
anion exchange column with quaternary amines, was able to separate
SA from other analogues.
The first attempt at isolating MTM SA involved equilibrating the column
twice with pH 7 phosphate buffer, loading the drug, washing with the pH7
buffer twice, and eluting with pH2 buffer/25% ACN. All three analogues
came off in the elutions.
4
9
14
19
24
29
4 6 8 10 12 14 16 18 20
SA
SK
SDK
5
10
15
20
25
30
35
10 11 12 13 14 15 16 17 18 19 20
Absorbanceat410nm(mAU)
Time (min)
Flow Through
wash 1
elution 1
elution 2
0
5
10
15
20
25
30
35
40
12 13 14 15 16 17 18 19 20
Absorbanceat410nm(mAU)
Time (min)
Flow through
Wash 1
Wash 2
Elution 1
Elution 2
Derivatization of SA
A coupling agent, PyBOP, is used with DIPEA, DCM, and a
desired side chain addition in order to form an SA-side chain
derivative. We used tryptophan, histidine, and phenylalanine as
side chain additions. An example reaction with tryptophan is
shown below.
HPLC spectral analysis revealed a new peak in the MTM-SA Trp
compound compared to SA. NMR and MS will later reveal the
compounds structure. Histidine and phenylalanine were analyzed
as well, but several new peaks appeared. Further testing to be
done.
The Cl- ion is a counter ion for the anion exchange column, so the new
washes included NaCl to wash off the MTM SK and MTM SDK in the
washes. After the drug was loaded, the drug was washed with 10mM
NaCl and eluted 3 times with 75% pH2 buffer/25% ACN. This time all three
analogues came off in the washes.
-5
0
5
10
15
20
25
30
35
40
45
14 14.5 15 15.5 16 16.5 17 17.5 18
Absorbanceat410nm(mAU)
Time (min)
Wash 1
Wash 2
Elution 1
Elution 2
In order to separate the MTM SA from the MTM SK and MTM SDK, ACN
was used in the washes. After the drug was loaded, it was washed 5
times with 90% pH 7/10% ACN and eluted 3 times with with 75% pH2
buffer/25% ACN. The washes contained mainly MTM SK and MTM SDK,
but some MTM SA did come out.
0
20
40
60
80
100
120
12 12.5 13 13.5 14 14.5 15 15.5 16
Absorbanceat410nm(mAU)
Time (min)
Flow Through
Wash 1
Wash 2
Elution 1
Elution 2
The wash for the final protocol included ACN and NaCl. After the
drug was loaded, it was washed 5 times with 1mM NaCl/10%
ACN, and eluted with 75% pH2 buffer/25% ACN.
MTM SK MTM SDK MTM SA
Anion exchange
quaternary amine
The three analogues are eluted off the HPLC at different times: MTM SA
at 15.7 min, MTM SK at 15.9, and MTM SDK at 16.6. This will show
which of the analogs are in a sample.
-8
-3
2
7
12
17
12 13 14 15 16 17 18 19 20
Phenyl Reaction
MTM SA
The phenyl reaction was successful as demonstrated by the peak
representing SA decreased and a new peak, the SA-side chain
derivative, was formed.
MTM SK MTM SDK MTM SA
PyBOP
DIPEA

More Related Content

Viewers also liked (13)

PPTX
Durex Loveville
pastel
PPTX
Adfap bootcamp for economus 2015 by ann mayeen magno
Paolo's Journey
PPT
Sistemas operacionais 13
Fernando Vieira
PPT
Reader profile
Clara Schj淡dt
PPTX
Foto rueda de alimentos
Priscilla Sanches Salles
TXT
livro x
rika Pereira
PDF
HCD Amato Audience Evaluation
CannonDesign
PPT
D A T O S R O B U S T I A N O
Omar Lima Quintana
DOCX
Hans persson
Hans Von Axelson
PPT
Literarisches Forum - Einf端hrung
kjakob
PDF
Demo 3 bass
martinkeane
PPT
Handlungsmacht 2008
Ralf Klamma
DOCX
Proposed plan- March
Vahesan際際滷
Durex Loveville
pastel
Adfap bootcamp for economus 2015 by ann mayeen magno
Paolo's Journey
Sistemas operacionais 13
Fernando Vieira
Reader profile
Clara Schj淡dt
Foto rueda de alimentos
Priscilla Sanches Salles
livro x
rika Pereira
HCD Amato Audience Evaluation
CannonDesign
D A T O S R O B U S T I A N O
Omar Lima Quintana
Hans persson
Hans Von Axelson
Literarisches Forum - Einf端hrung
kjakob
Demo 3 bass
martinkeane
Handlungsmacht 2008
Ralf Klamma
Proposed plan- March
Vahesan際際滷

Similar to AllisonFoster_SRFPoster_Fa14 (2) (12)

PPTX
ZTGLAHLAH
Zachary Golay
PPTX
critical synthesis Panchami Presentation (4TH SEM).pptx
sourav545818
PPTX
SBR Final Presentaion
Samantha Hancock
PDF
Nucleoside libray e-conference VRX-Harry
Harry An
PPT
Lead Optimization in Drug Discovery
avinashdhake3
PPT
Anti Neoplastic Agent.ppt
HRUTUJA WAGH
PPTX
characterization, synthesis Sourav final 4sem.pptx
sourav545818
PDF
Adventures in Metabolite Profiling with an Accurate Mass QTof
MicroConstants
PPTX
MEDCHEM PPT. Medicinal chemistry attributes of various drugs.
prateekprateek107
PPTX
Principle and Applications Of MBTH, NQS, FC and BM Reagents
Lakshmi Kalyani
PPTX
Feature products (july, 2017) cymtek labs, limited
Dayong Wei
PPTX
Feature products (july, 2017) cymtek labs, limited
Sophy Ding
ZTGLAHLAH
Zachary Golay
critical synthesis Panchami Presentation (4TH SEM).pptx
sourav545818
SBR Final Presentaion
Samantha Hancock
Nucleoside libray e-conference VRX-Harry
Harry An
Lead Optimization in Drug Discovery
avinashdhake3
Anti Neoplastic Agent.ppt
HRUTUJA WAGH
characterization, synthesis Sourav final 4sem.pptx
sourav545818
Adventures in Metabolite Profiling with an Accurate Mass QTof
MicroConstants
MEDCHEM PPT. Medicinal chemistry attributes of various drugs.
prateekprateek107
Principle and Applications Of MBTH, NQS, FC and BM Reagents
Lakshmi Kalyani
Feature products (july, 2017) cymtek labs, limited
Dayong Wei
Feature products (july, 2017) cymtek labs, limited
Sophy Ding
Ad

AllisonFoster_SRFPoster_Fa14 (2)

  • 1. Mithramycin (MTM) is an anticancer agent, produced by bacteria of the genus Streptomyces. MTM was popular in the 1960s to aid in the treatment of testicular carcinoma, chronic and acute myeloid leukemias, and hyperkalemia. MTMs anti-cancer potency lies in the ability to shut down the transcription of the proto-oncogenes through cross-linking GC-rich DNA. Unfortunately the large number of side effects caused the use of MTM to be discontinued. In recent years, MTM has been revisited as a potential anticancer agent because of the potential for semi- synthetic manipulation and development of biosynthetic analogues. One example of such work is demonstrated by inactivating the mtmW gene. This gene encodes for the enzyme responsible for the final step in the MTM biosynthetic pathway, but once deactivated, 3 new analogues are formed: MTM SA, MTM SK, and MTM SDK. MTM SK and MTM SDK improved the anti-cancer ability of the drug but, due in part to its negative charge at physiological pH, MTM SA shows reduced anticancer capabilities. Current research has shown that new derivatives of the MTM SA analogue produced by manipulating the side chain ending in the carboxylic acid have resulted in molecules with greater anti-cancer abilities than those of even MTM SK and MTM SDK. Further work was focused on optimizing the production and isolation of MTM-SA followed by further work to rationally design new drug molecules through modification of the terminal carboxylic acid side chain of MTM SA. Once developed the toxicity of the new compounds are investigated using the Jurkat human leukemia cell line. Improved Isolation, Derivatization, and Characterization of New Mithramycin Analogues Allison Foster, Sterling Brooks, Daniel Scott Department of Chemistry and Biochemistry, DePauw University, Greencastle, IN 46135, USA Summer 2014 Introduction Acknowledgments Mithramycin Analogue Biosynthesis Bacteria Growth and Drug Production Conclusions and Future Work Column 52666, a strong anion exchange column with a quaternary amine, successfully isolated SA SA isolation final protocol: equilibrate 5 times with pH7 potassium phosphate monobasic, load drug, wash 5 times with 90% 1mM NaCl/10% ACN, elute 3 times with 75% PBS pH 2/25% ACN An amino side chain is attached through a reaction composed of DCM, PyBOP, DIPEA, and a desired side chain Synthesized possible SA derivatives from phenylalanine with a successful reaction Will continue testing different side chains on the SA analogs Will complete cytotoxicity assays on Jurkat leukemia cell line, followed by a lung cancer cell line using isolated SK as a control for each The MTM analogues SA, SK, and SDK are are produced by the inactivation of the mtmW gene responsible for the last enzyme in the biosynthetic pathway of MTM. Isolation of SA The SA analogue has a caroboxylic acid that that allows for a negative charge at physiological pH. An anion exchange column was used to take advantage of the negative charge and separate this analogue from MTM SK and MTM SDK. The quaternary amine was the strongest and most effective anion exchange column S. Argillaceus is grown on R5A solid media for 5 days. A portion is cut out and transferred to liquid TSB media for two days of further promoted growth. A sample of this is transferred to R5A liquid media for 5 or more days in order to promote drug production. R5A Solid Media TSB Liquid Media R5A Liquid Media Jeff Hansen Wendy Tomamichel Dave Roberts DePauw University Science Research Fellows (SRF) Column characteristics for isolation of SA. Column 52667, a strong anion exchange column with quaternary amines, was able to separate SA from other analogues. The first attempt at isolating MTM SA involved equilibrating the column twice with pH 7 phosphate buffer, loading the drug, washing with the pH7 buffer twice, and eluting with pH2 buffer/25% ACN. All three analogues came off in the elutions. 4 9 14 19 24 29 4 6 8 10 12 14 16 18 20 SA SK SDK 5 10 15 20 25 30 35 10 11 12 13 14 15 16 17 18 19 20 Absorbanceat410nm(mAU) Time (min) Flow Through wash 1 elution 1 elution 2 0 5 10 15 20 25 30 35 40 12 13 14 15 16 17 18 19 20 Absorbanceat410nm(mAU) Time (min) Flow through Wash 1 Wash 2 Elution 1 Elution 2 Derivatization of SA A coupling agent, PyBOP, is used with DIPEA, DCM, and a desired side chain addition in order to form an SA-side chain derivative. We used tryptophan, histidine, and phenylalanine as side chain additions. An example reaction with tryptophan is shown below. HPLC spectral analysis revealed a new peak in the MTM-SA Trp compound compared to SA. NMR and MS will later reveal the compounds structure. Histidine and phenylalanine were analyzed as well, but several new peaks appeared. Further testing to be done. The Cl- ion is a counter ion for the anion exchange column, so the new washes included NaCl to wash off the MTM SK and MTM SDK in the washes. After the drug was loaded, the drug was washed with 10mM NaCl and eluted 3 times with 75% pH2 buffer/25% ACN. This time all three analogues came off in the washes. -5 0 5 10 15 20 25 30 35 40 45 14 14.5 15 15.5 16 16.5 17 17.5 18 Absorbanceat410nm(mAU) Time (min) Wash 1 Wash 2 Elution 1 Elution 2 In order to separate the MTM SA from the MTM SK and MTM SDK, ACN was used in the washes. After the drug was loaded, it was washed 5 times with 90% pH 7/10% ACN and eluted 3 times with with 75% pH2 buffer/25% ACN. The washes contained mainly MTM SK and MTM SDK, but some MTM SA did come out. 0 20 40 60 80 100 120 12 12.5 13 13.5 14 14.5 15 15.5 16 Absorbanceat410nm(mAU) Time (min) Flow Through Wash 1 Wash 2 Elution 1 Elution 2 The wash for the final protocol included ACN and NaCl. After the drug was loaded, it was washed 5 times with 1mM NaCl/10% ACN, and eluted with 75% pH2 buffer/25% ACN. MTM SK MTM SDK MTM SA Anion exchange quaternary amine The three analogues are eluted off the HPLC at different times: MTM SA at 15.7 min, MTM SK at 15.9, and MTM SDK at 16.6. This will show which of the analogs are in a sample. -8 -3 2 7 12 17 12 13 14 15 16 17 18 19 20 Phenyl Reaction MTM SA The phenyl reaction was successful as demonstrated by the peak representing SA decreased and a new peak, the SA-side chain derivative, was formed. MTM SK MTM SDK MTM SA PyBOP DIPEA